Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

MLA

Richard S. Finn, et al. Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.22499200.

APA

Richard S. Finn, Dennis J. Slamon, James G. Christensen, Ian Taylor, Carolyn D. Britten, David J. Cohen, Lee Anderson, Charles Ginther, Neil A. O’Brien, Amrita J. Desai, Dylan Conklin, & Ondrej Kalous. (2023). Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib. https://doi.org/10.1158/1535-7163.22499200

Chicago

Richard S. Finn, Dennis J. Slamon, James G. Christensen, Ian Taylor, Carolyn D. Britten, David J. Cohen, Lee Anderson, et al. 2023. “Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib,” April. doi:10.1158/1535-7163.22499200.